A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / email@example.com
This research study is being done to see if the study drug, IMCgp100, works and is safe as treatment for subjects with uveal melanoma who also test positive for HLA-A*0201. In this study IMCgp100 will be compared to three standard treatments: dacarbazine (a chemotherapy drug), ipilimumab (an immunotherapy drug), or pembrolizumab (an immunotherapy drug). This study is designed to find out if IMCgp100 can make subjects with uveal melanoma live longer and if IMCgp100 can make uveal melanoma tumors stop growing (or shrink).
This study is closed
Richard Carvajal, MD
|Have you been diagnosed with metastatic uveal melanoma?
|Have you previously received chemotherapy, immunotherapy, or target therapy?